Previous 10 | Next 10 |
– Data Presented at the 2021 ASCO GI Cancers Symposium – AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA ® ), AVEO’s vascular end...
Announcing its 2021 outlook, the microcap biopharma company AVEO Pharmaceuticals ([[AVEO]] +4.1%) says that the company is awaiting the U.S. launch for Tivozanib as a treatment for relapsed or refractory renal cell carcinoma.The FDA has also signed off the company’s Investigational New...
– Commercial Readiness Nearing Completion in Support of Potential Tivozanib U.S. Launch – – Updated IP Strategy Offers Potential for Tivozanib Patent Term Extension to November 2028 – – Corinne D. Epperly, MD, MPH, Appointed to Bo...
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 5:20 p.m. Eastern Time. Following the presentation, Mr. Bailey wi...
AVEO is preparing for the potential U.S. commercial launch for Tivozanib in R/R RCC. The FDA has set the PDUFA Date for March 31st, 2021. I expect to see an increase in trading volatility as we approach this critical date. AVEO has jumped though every hoop for the FDA, but approval is...
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20 a.m. Eastern Time. A live webcast of the presentation can be acces...
AVEO Pharmaceuticals (AVEO): Q3 GAAP EPS of -$0.33 misses by $0.10.Revenue of $3.6M (-86.0% Y/Y) beats by $0.18M.Cash, cash equivalents and marketable securities of $68.8M.Shares +2.16%.Press Release For further details see: AVEO Pharmaceuticals EPS misses by $0.10, beats on revenu...
- U.S. Commercial Launch Preparations Underway Supporting the Tivozanib PDUFA Target Action Date of March 31, 2021 – - Ficlatuzumab Worldwide Rights Regained; Final Results from Open Label Randomized Phase 2 HNSCC Study and Plans for Pivotal Program Expected in the Midd...
AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced that previously reported results from the Phase 1b/2 TiNivo study of oral (PO) tivozanib, AVEO’s next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) drug candidate, in comb...
AVEO Oncology (Nasdaq: AVEO) today announced the appointment of David Crist as Vice President of Sales. In this role, Mr. Crist will be responsible for building out AVEO’s sales force in anticipation of the potential approval and launch of tivozanib, the Company’s next-gen...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...